TL;DR Both Wegovy and Mounjaro are weekly weight loss injections that help people lose weight by reducing appetite, slowing digestion, and improving blood sugar control. They are typically prescribed for adults with obesity (BMI over 30) or those with weight-related health conditions. The main difference lies in how they work. Wegovy contains semaglutide and activates the GLP-1 hormone, which helps control appetite and glucose levels. Clinical trials show patients lose around 15% of body weight on average when combined with lifestyle changes. Mounjaro, which contains tirzepatide, activates two hormone pathways (GLP-1 and GIP). This dual mechanism can produce stronger metabolic effects and has shown up to 22.5% weight loss in clinical trials, making it one of the most powerful weight loss medications currently available. While Mounjaro often produces greater average weight loss, Wegovy remains highly effective and widely trusted, with strong long-term research and proven cardiovascular benefits. The best treatment depends on individual factors such as medical history, weight loss goals, medication tolerance, and metabolic response. A professional consultation helps determine which option is safest and most effective.

Weight loss injections are transforming how obesity and weight-related health conditions are managed in the UK. Treatments such as Wegovy and Mounjaro are now widely discussed because of their ability to help patients lose a significant amount of weight when combined with lifestyle changes. 

Both medications are highly effective and clinically proven, but they work in slightly different ways and can produce different results depending on the individual. Understanding the difference between Wegovy and Mounjaro, their mechanisms, clinical trial results, safety profile, and suitability can help patients make an informed decision.

Understanding Medical Weight Loss Injections

Weight loss injections belong to a class of medications known as GLP-1 receptor agonists. These medicines mimic hormones that regulate appetite, digestion, and blood sugar levels.

They work by:

• Reducing hunger signals in the brain
• Slowing stomach emptying so you feel full longer
• Improving blood sugar control
• Helping reduce calorie intake naturally

Unlike traditional diet pills, these medications target the biological mechanisms that influence appetite and metabolism.

Two of the most widely prescribed injections today are:

• Wegovy (semaglutide)
• Mounjaro (tirzepatide)

Both are administered as once-weekly injections and are typically prescribed for adults with obesity or weight-related medical conditions.

Wegovy vs Mounjaro for Weight Loss

When comparing Wegovy vs Mounjaro for weight loss, both medications show impressive results in clinical studies. However, their effectiveness and mechanisms differ slightly.

Wegovy

Wegovy contains semaglutide, a GLP-1 receptor agonist. It mimics the GLP-1 hormone, which regulates appetite and insulin secretion.

It works by:

• Reducing appetite in the brain
• Slowing gastric emptying
• Improving glucose metabolism

Wegovy has been extensively studied through the STEP clinical trial programme, which evaluated its impact on weight loss in patients with obesity.

In the STEP 1 trial, participants taking semaglutide achieved an average weight reduction of about 14.9% after 68 weeks compared to 2.4% in the placebo group.

Mounjaro

Mounjaro contains tirzepatide, which activates two hormone pathways:

• GLP-1 receptors
• GIP receptors

This dual hormone action can produce stronger metabolic effects.

Tirzepatide:

• Suppresses appetite
• Improves insulin sensitivity
• Enhances metabolic regulation

The SURMOUNT clinical trials demonstrated remarkable weight loss outcomes with tirzepatide. In the SURMOUNT-1 trial, patients achieved up to 22.5% weight loss depending on the dose.

Difference Between Wegovy and Mounjaro

Understanding the difference between Wegovy and Mounjaro helps clarify why results may vary.

Feature	Wegovy	Mounjaro
Active ingredient	Semaglutide	Tirzepatide
Hormone targets	GLP-1	GLP-1 and GIP
Injection frequency	Once weekly	Once weekly
Average weight loss	Around 15%	Up to 22%
Mechanism	Appetite control	Appetite + metabolic regulation

The key difference lies in hormone activation:

• Wegovy activates one appetite-regulating hormone pathway.
• Mounjaro activates two pathways, which may enhance metabolic effects and lead to greater weight reduction for some individuals.

However, this does not mean one medication is automatically better for every patient.

Semaglutide vs Tirzepatide: How They Work in the Body

The comparison of semaglutide vs tirzepatide explains why Mounjaro often produces stronger results.

Semaglutide Mechanism

Semaglutide works by mimicking the GLP-1 hormone.

This hormone helps regulate:

• Hunger signals in the hypothalamus
• Insulin release after meals
• Stomach emptying speed

The result is reduced appetite and improved blood sugar control.

Tirzepatide Mechanism

Tirzepatide activates both GLP-1 and GIP receptors.

GIP hormones influence:

• Fat metabolism
• Insulin sensitivity
• Energy balance

When combined with GLP-1 activation, the metabolic effects can be amplified.

This dual hormone mechanism is why tirzepatide has produced some of the highest weight loss results ever recorded in obesity trials.

Mounjaro vs Wegovy Results

Clinical trial data offer the most reliable insight into Mounjaro vs Wegovy results.

Wegovy Weight Loss Results

The STEP trial programme evaluated semaglutide across several large studies.

Key findings include:

STEP 1 Trial
Average weight loss: 14.9%

STEP 3 Trial
Weight reduction up to 16%

STEP 4 Trial
Patients maintaining treatment continued losing weight over time.

Many patients lose 10 to 15% of their body weight with Wegovy when combined with dietary changes and physical activity.

Mounjaro Weight Loss Results

The SURMOUNT trials evaluated tirzepatide for obesity treatment.

Key results include:

SURMOUNT 1 Trial

• 15 mg dose produced 22.5% weight loss
• Average reduction of over 20 kg in many patients

SURMOUNT 3 Trial

Participants achieved over 26% weight loss when tirzepatide was combined with lifestyle intervention.

These results represent some of the most significant outcomes ever observed in obesity medicine.

Is Wegovy Better Than Mounjaro?

The answer depends on several factors:

Individual metabolism

People respond differently to hormone therapies. Some individuals may experience excellent results with semaglutide, while others respond more strongly to tirzepatide.

Tolerability

Side effects vary between patients. If someone tolerates Wegovy better, they may stay on treatment longer and achieve better outcomes.

Medical history

Certain medical conditions or medications may influence which injection is recommended.

Weight loss goals

Patients aiming for higher weight reduction may benefit from medications with stronger metabolic effects.

In many cases, clinicians view Mounjaro as slightly more powerful, but Wegovy remains an extremely effective option.

Which Weight Loss Injection Works Best?

Determining which weight loss injection works best requires a personalised approach.

Healthcare professionals consider several factors:

• Body mass index
• Medical history
• Blood sugar levels
• Previous weight loss attempts
• Lifestyle habits
• Medication tolerance

Both injections are typically prescribed for individuals with:

• BMI over 30
• BMI over 27 with weight-related health conditions

These conditions may include:

• Type 2 diabetes
• Hypertension
• Sleep apnoea
• High cholesterol

A pharmacy consultation ensures the safest and most effective treatment plan.

Safety and Side Effects of Wegovy and Mounjaro

Both medications have been studied in large clinical trials and are considered safe when used under medical supervision.

Common side effects may include:

• Nausea
• Vomiting
• Constipation
• Diarrhoea
• Reduced appetite
• Stomach discomfort

These effects usually occur during the early stages of treatment and often improve as the body adjusts.

Gradual dose escalation is used to reduce the risk of side effects. Patients should always consult a healthcare professional before starting treatment.

Who Might Benefit Most From Wegovy?

Wegovy may be particularly suitable for:

• patients seeking steady gradual weight loss
• individuals sensitive to medication side effects
• people who respond well to GLP-1 medications
• patients with cardiovascular risk factors

Semaglutide has also been studied for heart health benefits, particularly in patients with obesity and cardiovascular disease.

The SELECT cardiovascular outcomes trial found that semaglutide reduced the risk of major cardiovascular events in patients with obesity.

Who Might Benefit Most From Mounjaro?

Mounjaro may be ideal for patients who:

• Require a larger weight loss
• Have insulin resistance or type 2 diabetes
• Have not responded well to other GLP-1 medications
• Want stronger appetite suppression

Because of its dual hormone mechanism, tirzepatide may deliver greater metabolic improvements for certain individuals.

Lifestyle Changes for Long-Term Weight Loss

Weight loss injections are not a standalone solution.

Successful treatment usually involves:

• improved dietary habits
• increased physical activity
• behavioural changes
• consistent medical monitoring

Clinical trials consistently show that combining medication with lifestyle support produces the best results.

At Cleckheaton Pharmacy, patients receive professional guidance alongside treatment to maximise long-term success.

Final Thoughts: Wegovy vs Mounjaro

Both medications represent major advancements in medical weight management. When comparing Wegovy vs Mounjaro, the key takeaway is that both treatments are highly effective and clinically validated.

Mounjaro may deliver greater average weight loss due to its dual hormone action, but Wegovy remains one of the most studied and trusted treatments for obesity. The best choice depends on individual health factors, treatment goals, and medical guidance.

If you are considering medically supervised weight loss, a consultation with a qualified healthcare provider can help determine the most appropriate option.

FAQs

Do some people do better on Wegovy than Mounjaro?

Yes. Individual responses vary based on metabolism, genetics, and hormone sensitivity. Some patients respond exceptionally well to semaglutide and achieve significant weight loss, even if average clinical trial results appear slightly lower than those of tirzepatide.

Why do I feel so much better on Wegovy?

Wegovy improves blood sugar stability, reduces appetite spikes, and slows digestion. These effects can stabilise energy levels and reduce cravings, which may make some individuals feel better physically and mentally during treatment.

Is Wegovy better for your heart than Mounjaro?

Semaglutide has strong cardiovascular evidence from the SELECT trial showing reduced risk of major heart events in people with obesity. Tirzepatide research is ongoing, but early studies also suggest positive cardiometabolic benefits.

What is the difference between Wegovy and Mounjaro doses?

Wegovy doses typically increase gradually from 0.25 mg to a maintenance dose of 2.4 mg weekly. Mounjaro doses range from 2.5 mg up to 15 mg weekly, depending on tolerance and treatment goals.